News|Articles|December 31, 2024

2024’s Biggest Marketing Stories

Author(s)Mike Hollan

Point of care messaging and AI resulted in more targeted campaigns over the past year.

Emerging Trends at the Intersection of AI & Marketing

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, talks about what's coming marketing with the use of AI.

From Identity to Margin: Securing Audience Measurement in Pharma Marketing

The industry must find a way to balance consumer privacy and a return on investment in pharma marketing.

Not Just Another Tactic: Why Pharmaceutical Brands Need to Build a Strategy Around Point of Care Messaging

Point of care messaging offers unique advantages in pharmaceutical marketing and should be a high priority in brand strategy discussions.

Thursday Night DTC Marketing: Q&A with Dan Switzer

Daiichi Sankyo’s head of US oncology business discusses the company’s first DTC television campaign for Enhertu.

Bringing Marketing to a New Audience: Q&A with Jeremy Truxal

Truxal discusses Exact Science’s first Spanish language TV commercial and campaign for Cologuard.

Using AI and Advanced Analytics Tools to Optimize Marketing Strategies

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how CMOs can leverage artificial intelligence and other advanced analytics tools to extract meaningful insights and optimize marketing strategies.

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.